Recent approaches and strategies in the generation of antihuman cytomegalovirus vaccines

Methods in Molecular Biology

Volumn 1119, Issue , 2014, Pages 311-348

  Boppana, Suresh B ^a   Britt, William J ^a  

^a NONE

Author keywords

Adaptive immunity; Animal models of CMV immunity; Congenital CMV infection; Immune evasion; Maternal infection; Maternal reinfection; Vaccine development; Vaccine testing

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DNA VACCINE;

ADAPTIVE IMMUNITY; ADOLESCENCE; ADULTHOOD; AGE; ALLOGRAFT; ARTICLE; BRAZIL; CANADA; CHILDHOOD; CLINICAL TRIAL (TOPIC); CONGENITAL INFECTION; COTE D'IVOIRE; CYTOMEGALOVIRUS INFECTION; DENMARK; DISEASE MODEL; DISEASE TRANSMISSION; EMBRYO DEVELOPMENT; GAMBIA; GENE FUNCTION; GRAFT RECIPIENT; HEARING IMPAIRMENT; HOSPITAL INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE EVASION; IMMUNOCOMPROMISED PATIENT; INDIA; INFANCY; INTRAUTERINE INFECTION; NEWBORN PERIOD; NONHUMAN; PATHOGENESIS; PERINATAL PERIOD; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; SEROCONVERSION; SEROPREVALENCE; SOUTH KOREA; UNITED KINGDOM; UNITED STATES; VACCINATION; VERTICAL TRANSMISSION; VIRUS GENE; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; CYTOMEGALOVIRUS; FEMALE; GENETICS; IMMUNOLOGY; METHODOLOGY; MOLECULAR BIOLOGY; PATHOGENICITY; VIROLOGY;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; HUMANS; MOLECULAR BIOLOGY; VACCINES, DNA;

EID: 84908538427     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-788-4_17     Document Type: Article

References (283)

1. Krech U, Konjajev Z, Jung M (1971) Congenital cytomegalovirus infection in siblings from consecutive pregnancies. Helv Paediatr Acta 26:355-362
2. Gold E, Nankervis GA (1976) Cytomegalovirus. In: Evans AS (ed) Viral infections of humans: epidemiology and control. Plenum, New York, pp 143-161
3. Pass RF et al (1981) Specifi c lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy. Infect Immun 34:166-170
4. Stagno S et al (1982) Maternal cytomegalovirus infection and perinatal transmission. Clin Obstet Gynecol 25:563-576
5. Marshall GS, Stout GG (2005) Cytomegalovirus seroprevalence among women of childbearing age during a 10-year period. Am J Perinatol 22:371-376
6. Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253-276
7. Cannon MJ, Schmidt DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20:202-213
8. Hyde TB, Schmidt DS, Cannon MJ (2010) Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 20:311-326
9. Hutto C et al (1985) Epidemiology of cytomegalovirus infections in young children: day care vs. home care. Pediatr Infect Dis 4:149-152
10. Stagno S et al (1986) Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus and clinical outcome. JAMA 256:1904-1908
11. Adler SP (1989) Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med 321:1290-1296
12. Seo S, Cho Y, Park J (2009) Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidiyt test. Korean J Lab Med 29:557-562
13. Yamamoto AY et al (2012) Early high CMV seroprevalence in pregnant women from a population with a high rate of congenital infection. Epidemiol Infect 3:1-5
14. Saraswathy TS et al (2011) Seroprevalence of cytomegalovirus infection in pregnant women and associated role in obstetric complications: a preliminary study. Southeast Asian J Trop Med Public Health 42:320-322
15. Akinbami AA et al (2011) Seroprevalence of cytomegalovirus antibodies amongst normal pregnant women in Nigeria. Int J Womens Health 3:423-428
16. Hayes D, Danks M, Givas H, Jack I (1972) Cytomegalovirus in human milk. N Engl J Med 287:177
17. Lang DJ, Kummer JF (1975) Cytomegalovirus in semen: observations in selected populations. J Infect Dis 132:472-473
18. Reynolds DW et al (1973) Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med 289:1-5
19. Alford CA, Stagno S, Pass RF (1980) Natural history of perinatal cytomegalovirus infection. In: Perinatal Infections. Excerpta Medica, Amsterdam, pp 125-147
20. Gold E, Nankervis GA (1982) Cytomegalovirus. In: Evans AS (ed) Viral infections of humans: epidemiology and control, 2nd edn. Plenum, New York, pp 167-186
21. Bate SL, Dollard SC, Cannon MJ (2010) Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 50:1439-1447
22. Schopfer K, Lauber E, Krech U (1978) Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy. Arch Dis Child 53:536-539
23. Vial P et al (1985) Serological study of cytomegalovirus, herpes simplex and rubella virus, hepatitis B and Toxoplasma gondii in 2 populations of pregnant women in Santiago, Chile. Bol Ofi cina Sanit Panam 99:528-538
24. Mussi-Pinhata MM et al (2009) Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 49:522-528
25. Dar L et al (2008) Congenital cytomegalovirus infection in a highly seropositive semiurban population in India. Pediatr Infect Dis J 27:841-843
26. Stagno S et al (1980) Breast milk and the risk of cytomegalovirus infection. N Engl J Med 302:1073-1076
27. Hamprecht K et al (2001) Epidemiology of transmission of cytomegalovirus from mother to preterm infants by breastfeeding. Lancet 357:513-518
28. Sohn YM et al (1992) Congenital cytomegalovirus infection in Korean population with very high prevalence of maternal immunity. J Korean Med Sci 7:47-51
29. van der Sande MAB et al (2007) Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West- African birth cohort. PLoS One 2:e492
30. Boppana SB et al (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344:1366-1371
31. Yamamoto AY et al (2010) Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirusimmune maternal population. Am J Obstet Gynecol 202(3):297:e1-297e8
32. Chandler SH, Handsfi eld HH, McDougall JK (1987) Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted diseases. J Infect Dis 155:655-660
33. Ishibashi K et al (2007) Association of the outcome of renal transplantation with antibody response to cytomegalovirus strainspecifi c glycoprotein H epitopes. Clin Infect Dis 45:60-67
34. Ross SA et al (2010) Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386-389
35. Fowler KB, Stagno S, Pass RF (1993) Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990. J Infect Dis 168:552-556
36. Preece PM et al (1986) Congenital cytomegalovirus infection: predisposing maternal factors. J Epidemiol Community Health 40: 205-209
37. Fowler KB, Stagno S, Pass RF (1991) Rates of congenital cytomegalovirus infection based on newborn screening in two populations over an eleven year interval. Pediatr Res 29:90A
38. Jordan MC et al (1973) Association of cervical cytomegaloviruses with venereal disease. N Engl J Med 288:932-934
39. Willmott FE (1975) Cytomegalovirus in female patients attending a VD clinic. Br J Vener Dis 51:278-280
40. Drew WL et al (1981) Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 143:188-192
41. Chandler SH et al (1985) The epidemiology of cytomegaloviral infection in women attending a sexually transmitted disease clinic. J Infect Dis 152:597-605
42. Sohn YM et al (1991) Cytomegalovirus infection in sexually active adolescents. J Infect Dis 163:460-463
43. Knox GE et al (1979) Comparative prevalence of subclinical cytomegalovirus and herpes simplex virus infections in the genital and urinary tracts of low income, urban females. J Infect Dis 140:419-422
44. Ahlfors K et al (1981) Secondary maternal cytomegalovirus infection causing symptomatic congenital infection. N Engl J Med 305:284
45. Stagno S et al (1982) Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 306:945-949
46. Ahlfors K et al (1983) Congenital cytomegalovirus infection: on the relation between type and time of maternal infection and infant’s symptoms. Scand J Infect Dis 15:129-138
47. Stagno S et al (1983) Congenital and perinatal cytomegaloviral infections. Semin Perinatol 7:31-42
48. Fowler KB et al (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663-667
49. Demmler GJ (1990) Infectious Diseases Society of America and Centers for Disease Control: summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 13:315-329
50. Boppana SB et al (1999) Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104:55-60
51. Ahlfors K, Ivarsson SA, Harris S (1999) Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand J Infect Dis 31:443-457
52. Yamamoto AY et al (2011) Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly seropositive population. Pediatr Infect Dis J 30:1043-1046
53. Townsend CL et al (2013) Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 56:1232-1239
54. Huang ES et al (1980) Molecular epidemiology of cytomegalovirus infections in women and their infants. N Engl J Med 303: 958-962
55. Renzette N et al (2011) Extensive genomewide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7:e1001344
56. Ross SA et al (2011) Mixed infection and strain diversity in congenital cytomegalovirus infection. J Infect Dis 204:1003-1007
57. Bale JF Jr et al (2001) Human cytomegalovirus a sequence and UL144 variability in strains from infected children. J Med Virol 65:90-96
58. Bale JF et al (1999) Cytomegalovirus transmission in child care homes. Arch Pediatr Adolesc Med 153:75-79
59. Chandler SH, McDougall JK (1986) Comparison of restriction site polymorphisms among clinical isolates and laboratory strains of human cytomegalovirus. J Gen Virol 67:2179-2192
60. Novak Z et al (2008) Cytomegalovirus strain diversity in seropositive women. J Clin Microbiol 46:882-886
61. Starr SE et al (1979) Impaired cellular immunity to cytomegalovirus in congenitally infected children and their mothers. J Infect Dis 140:500-505
62. Gehrz RC et al (1977) Specifi c cell-mediated immune defect in active cytomegalovirus infection of young children and their mothers. Lancet 2:844-847
63. Miles DJ et al (2008) CD4(+) T cell responses to cytomegalovirus in early life: a prospective birth cohort study. J Infect Dis 197:658-662
64. Tu W et al (2004) Persistent and selective defi ciency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 172:3260-3267
65. Marchant A et al (2003) Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest 111:1747-1755
66. Wang C et al (2011) Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 52:e11-13
67. Boppana SB, Britt WJ (1995) Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115-1121
68. Britt WJ et al (1990) An immunodominant linear epitope on the major envelope glcoprotein complex (gB) of human cytomegalovirus, In: VIII international congress of virology, Berlin
69. Fouts AE et al (2012) Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anticytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86:7444-7447
70. Nigro G et al (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350-1362
71. Visentin S et al (2012) Early pregnancy cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 55:497-503
72. Maidji E et al (2006) Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor- mediated transcytosis. Am J Pathol 168:1210-1226
73. Pereira L et al (2003) Human cytomegalovirus transmission from the uterus to the placenta correlates with the presence of pathogenenic bacteria and maternal immunity. J Virol 77:13301-13314
74. Walker S et al (2007) Ex vivo monitoring of human cytomegalovirus-specifi c CD8+ T-cell responses using QuantiFeron-CMV. Transpl Infect Dis 9:165-170
75. Mattes FM et al (2008) Functional impairment of cytomegalovirus specifi c CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 8:990-999
76. Zanghellini F et al (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180: 702-707
77. Hansen SG et al (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102-106
78. Sester M et al (2002) Sustained high frequencies of specifi c CD4 T cells restricted to a single persistent virus. J Virol 76:3748-3755
79. Gamadia LE et al (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101:2686-2692
80. Moss P, Khan N (2004) CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 65:456-464
81. Sylwester AW et al (2005) Broadly targeted human cytomegalovirus-specifi c CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673-685
82. Gyulai Z et al (2000) Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp 65, IE1-Exaon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specifi c CTSs. J Infect Dis 181:1537-1546
83. Lilleri D et al (2007) Development of human cytomegalovirus-specifi c T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 195:1062-1070
84. Baldanti F et al (2006) Human cytomegalovirus UL131A, UL130, and UL128 genes are highly conserved among fi eld isolates. Arch Virol 151:1225-1233
85. Lissauer D et al (2011) Cytomegalovirus seropositivity dramatically alters the maternal CD8+ T cell repertoire and leads to the accumulation of highly differentiated memory cells during human pregnancy. Hum Reprod 26:3355-3365
86. Li CR et al (1994) Recovery of HLArestricted cytomegalovirus (CMV)-specifi c T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971-1979
87. Reusser P et al (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373-1380
88. Walter EA et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038-1044
89. Rosa L et al (2007) Longitudinal assessment of cytomegalovirus (CMV)-specifi c immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195:633-644
90. Schooley RT et al (1983) Association of herpes virus infection with T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 308:307-313
91. Sester M et al (2001) Levels of virus-specifi c CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287-1294
92. Reusser P et al (1999) Cytomegalovirus (CMV)-specifi c T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 180:247-253
93. Pourgheysari B et al (2009) Early reconstitution of effector memory CD4+ CMV-specifi c T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 43:853-861
94. Razonable RR (2008) Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 14:4849-4860
95. Gallina A et al (1996) Human cytomegalovirus protein pp 65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals. J Gen Virol 77:1151-1157
96. Riddell SR, Greenberg PD (1994) Therapeutic reconstruction of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr Top Microbiol Immunol 189:9-34
97. Riddell SR, Greenberg PD (2000) T-cell therapy of cytomegalovirus and human immunodefi ciency virus infection. J Antimicrob Chemother 45:35-43
98. Komanduri KV et al (1998) Restoration of cytomegalovirus-specifi c CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:953-956
99. Autran B et al (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116
100. Bronke C et al (2005) Dynamics of cytomegalovirus (CMV)-specifi c T cells in HIV-1- infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 191:873-880
101. Boppana SB et al (1995) Virus specifi c antibody responses to human cytomegalovirus (HCMV) in human immunodefi ciency virus type 1-infected individuals with HCMV retinitis. J Infect Dis 171:182-185
102. Dylewski J, Chou S, Merigan TC (1983) Absence of detectable IgM antibody during cytomegalovirus disease in patients with AIDS [letter]. N Engl J Med 309:493
103. Rasmussen L et al (1994) Defi ciency in antibody response to human cytomegalovirus glycoprotein gH in human immunodefi ciency virus-infected patients at risk for cytomegalovirus retinitis. J Infect Dis 170:673-677
104. Arribas JR et al (1996) Cytomegalovirus encephalitis. Ann Intern Med 125:577-587
105. Evans PC et al (1999) Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of liver grafts. J Hepatol 31:913-920
106. Lautenschlager I et al (2006) Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 8:21-30
107. Myerson D, Hackman RC, Meyers JD (1984) Diagnosis of cytomegaloviral pneumonia by in situ hybridization. J Infect Dis 150: 272-277
108. Myerson D et al (1984) Widespread presence of histologically occult cytomegalovirus. Hum Pathol 15:430-439
109. Schleiss MR (2006) Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J 47: 65-72
110. Britt WJ, Boppana S (2004) Human cytomegalviurs virion proteins. Hum Immunol 65:395-402
111. Jonjic S et al (2008) Immune evasion of natural killer cells by viruses. Curr Opin Immunol 20:30-38
112. Jonjic S et al (1990) Effi cacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol 64:5457-5464
113. Jonjic S et al (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179:1713-1717
114. Koszinowski UH, Reddehase MJ, Jonjic S (1991) The role of CD4 and CD8 T cells in viral infections. Curr Opin Immunol 3: 471-475
115. Koszinowski UH et al (1987) Molecular analysis of herpesviral gene products recognized by protective cytolytic T lymphocytes. Immunol Lett 16:185-192
116. Krmpotic A et al (2003) Pathogenesis of murine cytomegalovirus infection. Microbes Infect 5:1263-1277
117. Polic B et al (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188:1047-1054
118. Shanley JD (1991) Murine models of cytomegalovirus associated pneumonitis. Transplant Proc 23:S12-S16
119. Shanley JD, Biczak L, Formon SJ (1993) Acute murine cytomegalovirus infection induces lethal hepatitis. J Infect Dis 167: 264-269
120. Koszinowski UH, Del Val M, Reddehase MJ (1990) Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol 154:189-220
121. Alcami A, Koszinowski UH (2000) Viral mechanisms of immune evasion. Immunol Today 21:447-455
122. Krmpotic A et al (2005) NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med 201:211-220
123. Zimmermann A et al (2005) A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med 201:1543-1553
124. LoPiccolo DM et al (2003) Effective inhibition of K(b)- and D(b)-restricted antigen presentation in primary macrophages by murine cytomegalovirus. J Virol 77:301-308
125. Lenac T et al (2006) The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med 203: 1843-1850
126. Krmpotic A et al (2001) The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med 190:1285-1296
127. Krmpotic A et al (2002) MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 3: 529-535
128. Kavanagh DG et al (2001) The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med 194:967-978
129. Hasan M et al (2005) Selective downregulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol 79:2920-2930
130. Hengel H et al (1999) Cytomegaloviral control of MHC class I function in the mouse. Immunol Rev 168:167-176
131. Smith HR et al (2002) Recognition of a virusencoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A 99:8826-8831
132. Upton JW, Kaiser WJ, Mocarski ES (2010) Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe 7:302-313
133. Lisnic VJ, Krmpotic A, Jonjic S (2010) Modulation of natural killer cell activity by viruses. Curr Opin Microbiol 14:530-539
134. Humphreys IR et al (2007) Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med 204: 1217-1225
135. Reddehase MJ et al (1994) The conditions of primary infection defi ne the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185-193
136. Mathys S et al (2003) Dendritic cells under infl uence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation. J Infect Dis 187:988-999
137. Spencer JV et al (2002) Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 76:1285-1292
138. Chang WL, Barry PA (2009) Attenuation of innate immunity by cytomegalovirus IL-10 establishes a long-term defi cit of adaptive antiviral immunity. Proc Natl Acad Sci U S A 107:22647-22652
139. Mandaric S et al (2012) IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMV-specifi c CD4 T cells and prolonged MCMV persistence. PLoS Pathog 8:e1002846
140. Scalzo AA et al (2007) The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol 85:46-54
141. Jonjic S, Bubic I, Krmpotic A (2006) Innate immunity to cytomegaloviruses. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister, Norfolk, UK, pp 285-321
142. Klenovsek K et al (2007) Protection from CMV infection in immunodefi cient hosts by adoptive transfer of memory B cells. Blood 110:3472-3479
143. Schlub TE et al (2011) Comparing the kinetics of NK cells, CD4, and CD8 T cells in murine cytomegalovirus infection. J Immunol 187:1385-1392
144. Walton SM et al (2008) The dynamics of mouse cytomegalovirus-specifi c CD4 T cell responses during acute and latent infection. J Immunol 181:1128-1134
145. Holtappels R et al (2008) CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model. Med Microbiol Immunol 197:125-134
146. Cekinovic D et al (2008) Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 82:12172-12180
147. Pavic I et al (1993) Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol 74(Pt 10):2215-2223
148. Scalzo AA, Yokoyama WM (2008) Cmv1 and natural killer cell responses to murine cytomegalovirus infection. Curr Top Microbiol Immunol 321:101-122
149. Vivier E et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49
150. Rapp M et al (1993) In vivo protection studies with MCMV glycoproteins gB and gH expressed by vaccinia virus. In: Michelson S, Plotkin SA (eds) Multidisciplinary approach to understanding cytomegalovirus disease. Excerpta Medica, Amsterdam, pp 327-332
151. Reddehase MJ et al (1987) CD8-positive T lymphocytes specifi c for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102-3108
152. Del Val M et al (1991) Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 65:3641-3646
153. Mohr CA et al (2010) A spread-defi cient cytomegalovirus for assessment of fi rst-target cells in vaccination. J Virol 84:7730-7742
154. Gonzalez Armas JC et al (1996) DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70: 7921-7928
155. Morello CS, Cranmer LD, Spector DH (2000) Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp 65). J Virol 74: 3696-3708
156. Hakki M et al (2003) Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 102:3060-3067
157. Slavuljica I et al (2010) Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest 120:4532-4545
158. Farrell HE, Shellam GR (1991) Protection against murine cytomegalovirus infection by passive transfer of neutralizing and nonneutralizing monoclonal antibodies. J Gen Virol 72:149-156
159. Farroway LN et al (2005) Transmission of two Australian strains of murine cytomegalovirus (MCMV) in enclosure populations of house mice (Mus domesticus). Epidemiol Infect 133:701-710
160. Gorman S et al (2006) Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J Gen Virol 87:1123-1132
161. Barry PA et al (2006) Nonhuman primate models of intrauterine cytomegalovirus infection. ILAR J 47:49-64
162. Assaf BT et al (2012) Patterns of acute rhesus cytomegalovirus (RhCMV) infection predict long-term RhCMV infection. J Virol 86: 6354-6357
163. Lockridge KM et al (1999) Pathogenesis of experimental rhesus cytomegalovirus infection. J Virol 73:9576-9583
164. Kaur A et al (1996) Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodefi ciency virus-infected rhesus macaques. J Virol 70:7725-7733
165. Yue Y, Zhou SS, Barry PA (2003) Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J Gen Virol 84:3371-3379
166. Kaur A et al (2002) Decreased frequency of cytomegalovirus (CMV)-specifi c CD4+ T lymphocytes in simian immunodefi ciency virusinfected rhesus macaques: inverse relationship with CMV viremia. J Virol 76:3646-3658
167. Kaur A et al (2003) Direct relationship between suppression of virus-specifi c immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol 77:5749-5758
168. Yue Y et al (2008) Evaluation of recombinant modifi ed vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med Microbiol Immunol 197:117-123
169. Yue Y et al (2007) Immunogenicity and protective effi cacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol 81:1095-1109
170. Wussow F et al (2013) A vaccine based on rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 87:1322-1332
171. Hansen SG et al (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodefi ciency virus challenge. Nat Med 15:293-299
172. Holtappels R et al (2001) Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specifi c for pp M83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). J Virol 75:6584-6600
173. Podlech J et al (2000) Murine model of interstitial cytomegalovirus pneumona in syngenic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infi ltrates after clearance of acute infection. J Virol 74:7496-7507
174. Holtappels R et al (2006) CD8 T-cell-based immunotherapy of cytomegalovirus disease in the mouse model of the immunocompromised bone marrow transplantation recipient. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister, Norfolk, UK, pp 383-419
175. Scalzo AA et al (1992) The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol 149:581-589
176. Scalzo AA et al (1990) Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med 171:1469-1483
177. Brown MG et al (1999) Localization on a physical map of the NKC-linked Cmv1 locus between Ly49b and the Prp gene cluster on mouse chromosome 6. J Immunol 163:1991-1999
178. Webb JR, Lee SH, Vidal SM (2002) Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match. Genes Immun 3:250-262
179. Lee SH et al (2001) Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 28:42-45
180. Depatie C et al (1999) Assessment of Cmv1 candidates by genetic mapping and in vivo antibody depletion of NK cell subsets. Int Immunol 11:1541-1551
181. Cheng TP et al (2008) Ly49h is necessary for genetic resistance to murine cytomegalovirus. Immunogenetics 60:565-573
182. Cooper MA, Yokoyama WM (2010) Memory- like responses of natural killer cells. Immunol Rev 235:297-305
183. Elliott JM, Yokoyama WM (2011) Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 32:364-372
184. Fodil-Cornu N et al (2008) Ly49h-defi cient C57BL/6 mice: a new mouse cytomegalovirus- susceptible model remains resistant to unrelated pathogens controlled by the NK gene complex. J Immunol 181: 6394-6405
185. Hadaya K et al (2008) Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant 8:2674-2683
186. Bacon L et al (2004) Two human ULBP/ RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 173:1078-1084
187. Bauer S et al (1999) Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 285:727-729
188. Chalupny NJ et al (2003) ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 305:129-135
189. Eagle RA et al (2006) Regulation of NKG2D ligand gene expression. Hum Immunol 67: 159-169
190. Eagle RA et al (2009) ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol 39:3207-3216
191. Rolle A et al (2003) Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 171:902-908
192. Jonjic S et al (1989) Site-restricted persistent cytomegalovirus infection after selective longterm depletion of CD4+ T lymphocytes. J Exp Med 169:1199-1212
193. Lucin P et al (1992) Gamma interferondependent clearance of cytomegalovirus infection in salivary glands. J Virol 66:1977-1984
194. Holtappels R et al (1998) Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate- early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infi ltrates. J Virol 72:7201-7212
195. Reddehase MJ et al (1985) Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 55:264-273
196. Kurz S et al (1997) Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol 71:2980-2987
197. Baroncelli S et al (1997) Cytomegalovirus and simian immunodefi ciency virus coinfection: longitudinal study of antibody responses and disease progression. J Acquir Immune Defi c Syndr Hum Retrovirol 15:5-15
198. Sequar G et al (2002) Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodefi ciency virus: pathogenesis. J Virol 76:7661-7671
199. Reuter JD et al (2004) Systemic immune defi - ciency necessary for cytomegalovirus invasion of the mature brain. J Virol 78:1473-1487
200. Woolf NK, Jaquish DV, Koehrn FJ (2007) Transplacental murine cytomegalovirus infection in the brain of SCID mice. Virol J 4:26
201. Bia FJ et al (1983) Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis 5:177-195
202. Bia FJ, Miller SA, Davidson KH (1984) The guinea pig cytomegalovirus model of congenital human cytomegalovirus infection. Birth Defects 20:233-241
203. Griffi th BP et al (1986) Inbred guinea pig model of intrauterine infection with cytomegalovirus. Am J Pathol 122:112-119
204. Borune N et al (2001) Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guniea pig model of congenital CMV infection. J Infect Dis 183:59-64
205. Schleiss MR (2007) Comparison of vaccine strategies against congenital CMV infection in the guinea pig model. J Clin Virol 41:224-230
206. Harrison CJ et al (1995) Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis 172:1212-1220
207. Bratcher DF et al (1995) Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 172:944-950
208. Chatterjee A et al (2001) Modifi cation of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 183:1547-1553
209. Woolf NK (1991) Guinea pig model of congenital CMV-induced hearing loss: a review. Transplant Proc 23:32-34
210. Park AH et al (2010) Development of cytomegalovirus- mediated sensorineural hearing loss in a guinea pig model. Arch Otolaryngol Head Neck Surg 136:48-53
211. Britt WJ, Cekinovic D, Jonjic S (2013) Murine model of neonatal cytomegalovirus infection. In: Reddehasse M (ed) Cytomegaloviruses. Cassister, London
212. Koontz T et al (2008) Altered development of the brain after focal herpesvirus infection of the central nervous system. J Exp Med 205:423-435
213. Kosmac K et al (2013) Glucocortiocoid treatment of MCMV infected newborn mice attenuates CNS infl ammation and limits defi cits in cerebellar development. PLoS Pathog 9:e1003200
214. Stagno S et al (1977) Congenital cytomegalovirus infection: occurrence in an immune population. N Engl J Med 296:1254-1258
215. Adler SP et al (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171:26-32
216. Pass RF et al (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191-1199
217. Hansen SG et al (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527
218. Wloch MK et al (2008) Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197:1634-1642
219. Griffi ths PD et al (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377: 1256-1263
220. Bernstein DI et al (2009) Randomized, doubleblind, phase I trial of alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484-493
221. Heineman TC et al (2006) A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193:1350-1360
222. La Rosa C et al (2012) Clinical evaluation of safety and immunogenicity of PADREcytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 205: 1294-1304
223. Snydman DR (1993) Review of the effi cacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients. Transplant Proc 25:25-26
224. Yeager AS et al (1981) Prevention of transfusion- acquired cytomegalovirus infections in newborn infants. J Pediatr 98: 281-287
225. Rubin R (2002) Clinical approach to infection in the compromised host. In: Rubin R, Young LS (eds) Infection in the organ transplant recipient. Kluwer Academic, New York, pp 573-679
226. Snydman DR et al (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 317:1049-1054
227. Nigro G, Adler SP (2011) Cytomegalovirus infections during pregnancy. Curr Opin Obstet Gynecol 23:123-128
228. Hedlund M et al (2009) Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 183:340-351
229. Iwasenko JM et al (2011) Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 203:1526-1533
230. La Torre R et al (2006) Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 43:994-1000
231. Pereira L, Maidji E (2008) Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol 325:383-395
232. Scott GM et al (2012) Cytomegalovirus infection during pregnancy with maternofetal transmission induces a proinfl ammatory cytokine bias in placenta and amniotic fl uid. J Infect Dis 205:1305-1310
233. Cui X et al (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralzing antibodies comparable to natural infection. Vaccine 26:5760-5766
234. Gerna G et al (2008) Human cytomegalvirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells but not fi broblasts, early during primary infection. J Gen Virol 89:853-865
235. Lilleri D et al (2012) Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 32:1324-1331
236. Jacobson MA et al (2009) A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 27:1540-1548
237. Boppana SB, Britt WJ (1996) Recognition of human cytomegalovirus gene products by HCMV-specifi c cytotoxic T cells. Virology 222:293-296
238. Borysiewicz LK et al (1988) Human cytomegalovirus- specifi c cytotoxic T cells: their precursor frequency and stage specifi city. Eur J Immunol 18:269-275
239. Wills MR et al (1996) The human cytotoxic T lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp 65: frequency, specifi city and T-cell receptor usage of pp65-specifi c CTL. J Virol 70: 7569-7579
240. Pass RF et al (1995) A phase I trial of BIOCINE CMV gB vaccine in seronegative adults. In: Fifth international cytomegalovirus conference, Stockholm, Sweden
241. Sabbaj S et al (2011) Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 203:1534-1541
242. Bubic I et al (2004) Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 78:7536-7544
243. Crnkovic-Mertens I et al (1998) Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol 72:1377-1382
244. Chang WL et al (2009) Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology 390:330-337
245. Logsdon NJ et al (2011) Design and analysis of rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human cytomegalovirus. PLoS One 6:e28127
246. Jones BC et al (2002) Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Natl Acad Sci U S A 99:9404-9409
247. Stagno S et al (1982) Prevalence and importance of congenital cytomegalovirus infection in three different populations. J Pediatr 101:897-900
248. Adler SP et al (1996) Prevention of child-tomother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J 15:240-246
249. Picone O et al (2009) A 2-year study on cytomegalovirus infection during pregnancy in a French hospital. BJOC 116:818-823
250. Paya CV et al (2004) Effi cacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4: 611-620
251. Kotton CN et al (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779-795
252. Asberg A et al (2009) Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 9:1205-1213
253. Ljungman P et al (2008) Manamagement of CMV, HHV-6, HHV-7 and Kaposi-sarcoma associated herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 42: 227-240
254. Tomblyn M et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant 15:1143-1238
255. Drew WL et al (1984) Multiple infections by cytomegalovirus in patients with acquired immune defi ciency syndrome: documentation by Southern blot hybridization. J Infect Dis 150:952-953
256. Burkhardt C et al (2009) Glycoprotein N subtypes of human cytomegalovirus induce a strain-specifi c antibody response during natural infection. J Gen Virol 90:1951-1961
257. Dal Monte P et al (2001) The product of human cytomegalovirus UL73 is a new polymorphic structural glycoprotein (gpUL73). J Hum Virol 4:26-34
258. Gnann JW et al (1988) Infl ammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol 132:239-248
259. Rasmussen L et al (2002) The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates. J Virol 76: 10841-10848
260. Pass RF et al (2006) Congenital cytomegalovirus infection following fi rst trimester maternal infection: symptoms at birth and outcome. J Clin Virol 35:216-220
261. Hodson EM et al (2005) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev CD003774
262. Enders G et al (2011) Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 52:244-246
263. Andersen H et al (1979) A prosepctive study on the incidence and signifi cance of congenital cytomegalovirus infection. Acta Paediatr Scand 68:329-336
264. Larke RBP et al (1980) Congenital cytomegalovirus infection in an urban Canadian community. J Infect Dis 142:647-653
265. Peckham CS et al (1983) Cytomegalovirus infection in pregnancy: preliminary fi ndings from a prospective study. Lancet 1:1352-1355
266. Child SJ et al (2004) Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J Virol 78:197-205
267. Brune W, Nevels M, Shenk T (2003) Murine cytomegalovirus m41 open reading frame encodes a Golgi-localized antiapoptotic progein. J Virol 77:11633-11643
268. Jurak I et al (2008) Murine cytomegalovirus m38.5 protein inhibits Bax-mediated cell death. J Virol 82:4812-4822
269. Cam M et al (2010) Cytomegaloviruses inhibit Bak- and Bax-mediated apoptosis with two separate viral proteins. Cell Death Differ 17:655-665
270. Skaletskaya A et al (2001) A cytomegalovirusencoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci U S A 98:7829-7834
271. Brune W et al (2001) Secreted virus-encoded proteins refl ect murinr cytomegalovirus productivity in organs. J Infect Dis 184: 1320-1324
272. Lenac T et al (2008) Murine cytomegalovirus regulation of NKG2D ligands. Med Microbiol Immunol 197:159-166
273. Lodoen MB et al (2004) The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60- NKG2D interactions. J Exp Med 200: 1075-1081
274. McCormick AL et al (2003) Differential function and expression of the viral inhibitor of caspase 8-induced apoptosis (vICA) and the viral mitochondria-localized inhibitor of apoptosis (vMIA) cell death suppressors conserved in primate and rodent cytomegaloviruses. Virology 316:221-233
275. Chalupny NJ et al (2006) Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 346:175-181
276. Fruh K, Yang Y (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11: 76-81
277. Bubeck A et al (2002) The glycoprotein gp48 of murine cytomegalovirusL proteasomedependent cytosolic dislocation and degradation. J Biol Chem 277:2216-2224
278. Vidal SM, Lanier LL (2006) NK cell recognition of moouse cytomegalovirus-infected cells. Curr Top Microbiol Immunol 298: 183-206
279. Babic M et al (2010) Cytomegalovirus immunoevasion reveals the physiological role of “missing self” recognition in natural killer cell dependent virus control in vivo. J Exp Med 207:2663-2673
280. Tomazin R et al (1999) Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD+ T cells. Nat Med 5:1039-1043
281. Jackson SE, Mason GM, Wills MR (2011) Human cytomegalovirus immunity and immune evasion. Virus Res 157:151-160
282. Arora N et al (2010) Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis 202:1800-1803
283. Rivera LB et al (2002) Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics 110: 762-767